Substance

Opioids

Publications

Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription‑Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial

Bastien G., Abboud A., McAnulty C., Elkrief L., Ledjiar O., Socias M.E., Le Foll B., Bahji A., Brissette S., Marsan S., Jutras‑Aswad D., Journal of Dual Diagnosis, 2024

Opioid prescribing requirements to minimize unused medications after an emergency department visit for acute pain: a prospective cohort study

Daoust R., Paquet J., Emond M., Iseppon M., Williamson D., Yan J.W., Perry J.J., Huard V., Lavigne G., Lee J., Lessard J., Lang E., Cournoyer A., CMAJ : Canadian Medical Association Journal, 2024

HIV incidence and factors associated with HIV risk among people who inject drugs engaged with harm-reduction programmes in four provinces in South Africa: a retrospective cohort study

Artenie A., Perry R., Mahaso M., Jankie T., McNaughton A.L., Stone J., Vickerman P., Scheibe A., The Lancet HIV, 2024

Examining the association between fentanyl use and perceived adequacy of methadone dose: a retrospective cohort study

Young S, Raboud J, Dodd Z, DeBeck K, Milloy MJ, Wilson D, Hayashi K, Bayoumi AM, Fairbairn N, Drug Alcohol Depend

Barriers and facilitators to accessing opioid agonist therapy for street-involved adolescents and young adults in Vancouver

Gallant K, Nijjar P, DeBeck K, Cui M, Kerr T, J Addict Med

Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study

Bouthillier A, Bastien G, McAnulty C, Bakouni H, Le Foll B, Socias ME, Jutras-Aswad D., Harm Reduct J. 2025

Cannabis use and illicit opioid cessation among people who use drugs living with chronic pain

Kitchen C, Socías ME, Sayre EC, Hayashi K, DeBeck K, Milloy MJ, Kerr T, Reddon H, Drug Alcohol Rev

Experiences of Healthcare Professionals Working in Injectable Opioid Agonist Treatment Programs: A Qualitative Thematic Analysis

Gadimova, F; Jackson, J., Journal of Addictions Nursing

Illicit drug toxicity from opioid, stimulant or sedative use in adolescents: results of a Canadian one‑time cross‑sectional study

Matthew Carwana, Eva Moore, Helia Shariati, Hasina Samji, Nicholas Chadi, Paediatrics & Child Health, 2025

Differences in overdose rates by gender at supervised consumption services: an explanatory sequential mixed methods study

Muel, E., Fan, E., Ginn, C., & Jackson, J., Drugs: Education, Prevention and Policy

The effects of a provincial opioid prescribing standard on prescribing for pain in adults: an interrupted time‑series analysis

Dimitra Panagiotoglou, Sandra Peterson, M. Ruth Lavergne, Tara Gomes, Rashmi Chadha, Philippa Hawley, Rita McCracken, Canadian Medical Association Journal (CMAJ), 2025

Role of Pharmacists in Addiction Medicine in Canada’s Publicly Funded Health Care Systems: A Qualitative Study

Weibe, A., Pecson, R., Coupland, M., Halpape, K., Can J Hospital Pharm.

Binge Drug Injection in a Cohort of People Who Inject Drugs in Montreal: Characterizing the Substances and Social Contexts Involved

Nanor Minoyan, Stine Bordier Høj, Didier Jutras‑Aswad, Sarah Larney, Valérie Martel‑Laferrière, Marie‑Pierre Sylvestre, Julie Bruneau, International Journal of Mental Health and Addiction, 2025

Examining opioid agonist treatment (OAT) site operations and early signals of change in the first year of British Columbia’s drug decriminalization policy: Insights from a provincial survey

Russell,C., Law, J., Hodgson, K., Mackinnon, L., Shahin, R., Crichlow, F., Patenaude, S., Imtiaz, S., Rhem, J., Ali, F., Canadian Journal of Public Health

Primary care physician characteristics associated with becoming opioid agonist treatment prescribers in British Columbia: a retrospective case‑control study

Dimitra Panagiotoglou, Sandra Peterson, M. Ruth Lavergne, Tara Gomes, Rashmi Chadha, Cheyenne Johnson, Rita McCracken, Harm Reduction Journal, 2025

The erosion of safer supply programs in Ontario, Canada: A dangerous step backward

Ali, F., Sprakes, A., Mende-Gibson, J., Russell,C., Shaw, A., Bonn, M., Celinski, A., Kaminski, N., Karamouzian, M., Strike, C., Rhem, J., Drug Science, Policy and Law

Indigenous peoples and medications for opioid use disorders: A scoping review

Gala N, Dobischok S, Bernett P, Parker DG, O’Callahan A, Zentner D, Huson K, Tomaro J, Wendt DC., Psychol Addict Behav. 2025

Exploring unregulated substance use health data in Ontario, Canada: Identifying gaps, addressing challenges, and uncovering opportunities

Ali, F., Law, J., Russell, C., Imtiaz, S., Bayoumi, A., Werb, D., Rhem, J., Front. Public Health

Concordance Between Urine Drug Screening and Self-Reported Use in the Context of a Pragmatic Randomized-Controlled Trial in People with Prescription-Type Opioid Use Disorder: Concordance entre le dépistage de drogues dans l’urine et l’usage autodéclaré dans le contexte d’un essai pragmatique contrôlé à répartition aléatoire chez des personnes présentant un trouble lié à l’usage d’opioïdes vendus sur ordonnance

Bastien G, Abboud A, McAnulty C, Mahroug A, Le Foll B, Socias ME, Juteau LC, Dubreucq S, Jutras-Aswad D., Can J Psychiatry. 2025

Impacts of the COVID-19 Pandemic on Opioid Use Disorder and Services for American Indian and Alaska Native Communities

Parker DG, Radin S, Sorlagas N, Wendt DC., Health Res. 2025

The Effect of Opioid Agonist Treatment on Injection-Related Sequelae: A Population-Based Observational Study

Lim J, Bruneau J, Platt RW, Panagiotoglou D., Drug Saf. 2025

Harnessing telemedicine to deliver patient‑centered opioid agonist treatment within a community‑based harm reduction service: a mixed methods evaluation

Stine Bordier Høj, Rémi Coignard‑Friedman, Aissata Sako, Catherine de Montigny, Marie‑Ève Beauchemin‑Nadeau, Robert Léandre, Nanor Minoyan, Geneviève Boyer‑Legault, Sofiane Chougar, Sara‑Kim Lamont, Julie Bruneau, Harm Reduction Journal , 2025

Longitudinal polysubstance use patterns and non-fatal overdose: a repeated measures latent class analysis

Karamouzian M, Cui Z, Hayashi K, DeBeck K, Reddon H, Buxton J, Kerr T, Int J Drug Policy

Predicting Fatal Drug Poisoning Among People Living with HIV‑HCV Co‑Infection

Mélanie Bédard, Erica Em Moodie, Joseph Cox, John Gill, Sharon Walmsley, Valérie Martel‑Laferrière, Curtis Cooper, Marina B Klein, Canadian Liver Journal, 2025

The impact of the COVID‑19 pandemic on social determinants of health, mental health, and substance use among key populations affected by sexually transmitted and blood‑borne infections in Canada

Apelian H., Aho J., Wong E., Cox J., Canadian Journal of Public Health, 2024

Substance

Opioids

Publications

Topic

Emergency care

decriminalisation

Harm reduction

Law enforcement/incarceration

Opioid agonist treatment

Prescription monitoring

Psychosocial intervention

Recovery

Sexually transmitted & blood-borne infections

Substance

Alcohol

Cannabis

Injectable drug use

Opioids

Tobacco/nicotine

Stimulants